Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV
Coburn S, Pimentel N, Leyden W, Kitahata M, Moore R, Althoff K, Gill M, Lang R, Horberg M, D'Souza G, Hussain S, Dubrow R, Novak R, Rabkin C, Park L, Sterling T, Neugebauer R, Silverberg M, AIDS F. Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 393-398. DOI: 10.1097/qai.0000000000003436.Peer-Reviewed Original ResearchNon-AIDS-defining cancersAIDS-defining cancersCancer riskAntiretroviral therapyAntiretroviral therapy classNorth American AIDS Cohort CollaborationCompare cancer riskCancer risk differencesLoss to follow-upInfection-related cancersFollow-upMarginal structural modelsIncident cancerIndividual cancer typesAntiretroviral therapy initiationLonger-term follow-upDuration of follow-upCohort CollaborationCohort studyHazard ratioRisk differenceMonths follow-upPP trialINSTI-based ARTPWH